ANAVEX 2-73: Journal of Psychopharmacology Publishes Anti-Amnesic and Neuroprotective Data Against Amyloid Toxicity For First of a New Class in Alzheimer’s Disease

Profile comparison to donepezil, citing greater potential benefits Califon, NJ – September 13, 2010 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced that the Journal of Psychopharmacology has published an original paper showing that ANAVEX 2-73 and its only and active metabolite ANAVEX 19-144 alleviate neurotoxicity and cognition deficits associated with Alzheimer’s disease.…

Dr. Cameron Durrant Named One of PharmaVOICE’s 100 Most Inspiring People in the Pharmaceutical Industry for 2010

Recognized for leadership, innovation in annual ranking of top 100 industry professionals Califon, NJ — August 30, 2010 — Anavex Life Sciences Corp., (“Anavex” or the “Company”) (OTCBB: AVXL) is pleased to announce that Dr. Cameron Durrant, the company’s Executive Chairman, has been named in this year’s “PharmaVOICE 100” as one of the 100 most…

Anavex Appoints Contract Research Organizations to Initiate Phase I/IIa Clinical Programs, Regulatory Strategies in Alzheimer’s Disease

Califon, NJ/Basel, Switzerland/Dresden, Germany – August 10, 2010 — Anavex Life Sciences Corp. (“ANAVEX”) (OTCBB: AVXL) today announced that it has signed a definitive master services agreement with Genesis BioPharma Group (“Genesis”) and ABX-CRO Advanced Pharmaceutical Services (“ABX-CRO”) to begin clinical studies and regulatory filings  for ANAVEX 2-73, its lead compound for the treatment of…

Anavex Reports Animal Study Results as Lead Alzheimer’s Compound Approaches Phase 1 Clinical Trials

Geneva, Switzerland — May 4, 2010 — Anavex Life Sciences Corp. (“ANAVEX”) (OTCBB: AVXL) is pleased to report promising results from animal studies with ANAVEX 2-73, the company’s lead compound for the treatment and modification of Alzheimer’s disease.ANAVEX 2-73 is the first of a new class of drugs that target mitochondrial dysfunction thought to be…

Anavex Comments on Failure of Pfizer and Medivation’s Dimebon

Geneva, Switzerland — March 3, 2010 — Anavex Life Sciences Corp. (“ANAVEX”) (OTCBB: AVXL) today issued a statement following today’s announcement from Pfizer and Medivation (NASDAQ:MDVN) that their investigational Alzheimer’s drug Dimebon did not meet either its co-primary or secondary endpoints compared to placebo during pivotal Phase 3 clinical trials. “While this is disappointing for…

Anavex Contracts FORENAP Pharma for Pre-Clinical Trials of ANAVEX 2-73 in Alzheimer’s Disease.

Geneva, Switzerland — September 30, 2009 — Anavex Life Sciences Corp. (“ANAVEX” or the “Company”) (OTCBB: AVXL) has selected FORENAP Pharma EURL (“FORENAP”) as the contract research organization (CRO) for Phase I clinical trials of ANAVEX 2-73, the company’s lead Alzheimer’s drug candidate.  FORENAP has been involved in pre-clinical and clinical research for 20 years…